LEF1 and hepatocellular carcinoma: Thus, these findings demonstrate that a new activated pathway, LEF1-miR-HCC1-NFIX, contributes to oncogenic activities in HCC, which could enhance the understanding between miRNAs and HCC development and could have potential value for clinical application in treating HCC.